Treatment of Lichen Simplex Chronicus (LSC)

1. Identify and Treat Underlying Causes First

• Atopic dermatitis, allergic contact dermatitis, psoriasis, stasis dermatitis, tinea
• Systemic causes of pruritus (hepatic, renal, thyroid, lymphoma)
• Anxiety, depression, obsessive-compulsive disorder, localized neuropathic itch

2. Topical Corticosteroids (First-line)

• Start with a high-potency agent (e.g., clobetasol propionate, betamethasone dipropionate) to reduce inflammation and pruritus and "thin down" the hyperkeratosis
• Transition to medium- or lower-potency steroids as lesions resolve to avoid steroid-induced atrophy
• Do NOT use high-potency agents indefinitely

• Occlusive dressings increase penetration and physically block scratching
• Flurandrenolide tape (Cordran) is particularly effective - it can be cut to fit each lesion and provides simultaneous occlusion and anti-inflammatory effect
• Hydrocolloid dressings applied repeatedly can lead to sustained improvement
• In the most severe cases, complete occlusion with an Unna boot can break the cycle

3. Intralesional Corticosteroids

• Triamcinolone suspension at 2.5-5 mg/mL injected intralesionally for persistent, thick plaques
• Inject at the correct depth - too superficial risks epidermal/dermal atrophy and depigmentation (may last months)
• Avoid injection into infected lesions (risk of abscess)

4. Topical Non-Steroidal Antipruritic Agents

5. Systemic / Adjunct Pharmacotherapy

• Antihistamines: hydroxyzine, diphenhydramine - helpful especially for nocturnal itch
• Oral doxepin: for severe or debilitating cases (sedating tricyclic with strong antihistamine and anxiolytic properties)
• Gabapentinoids (gabapentin, pregabalin): useful when there is a neuropathic itch component
• Antidepressants: address co-morbid anxiety/depression and reduce itch centrally
• Anxiolytics / clonazepam: for cases strongly driven by anxiety or OCD
• JAK inhibitors and biologics (dupilumab, etc.): increasingly used in refractory type-2 inflammation-driven cases, based on emerging data

6. Procedural Treatments

• Botulinum toxin A injections: can be curative by blocking acetylcholine-mediated itch signaling
• Cryotherapy: useful in select cases
• Fractional laser resurfacing: emerging evidence for recalcitrant plaques
• Transcutaneous electrical stimulation / focused ultrasound: adjunct options

7. Phototherapy

• Narrowband UVB or PUVA can be used for widespread or refractory cases
• Useful when systemic immunosuppressants are not desired

8. Behavioral and Psychological Interventions

• Patient education: explain the itch-scratch cycle; emphasize that avoiding scratching is necessary even when itch is still present
• Behavioral modification / habit reversal therapy
• Informal insight-oriented psychotherapy
• Application of topical agents as a "substitute" for rubbing/scratching (gives hands something to do)
• Stress reduction, addressing underlying psychiatric comorbidities

Key Points

• Recurrences are frequent even after successful treatment; clearance of one lesion may precede onset of another
• Pruritus is typically worse during inactivity (bedtime, night)
• Genital/perianal LSC may require systemic agents due to poor tolerability of topicals in sensitive areas
• A multimodal, individualized approach is most effective

• Andrews' Diseases of the Skin: Clinical Dermatology, p. 71
• Dermatology 2-Volume Set 5e, p. 129
• Textbook of Family Medicine 9e, p. 932
• Moshkovich M et al. "Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies." Am J Clin Dermatol 2025. PMID 40855389